Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

ading dose) or TYKERB alone (1500 mg QD). Patients were heavily pre-treated and had received a median of six prior anti-cancer regimens. Patients had received a median of three prior lines of trastuzumab (1).

The primary endpoint of the study was progression-free survival, and secondary endpoints included clinical benefit rate (CR+PR+SD greater than or equal to 24 weeks), response rate, and overall survival. If patients progressed on the TYKERB monotherapy arm after four weeks of therapy, they could cross over to receive the combination of TYKERB + trastuzumab. Adverse events were similar in both arms, with Grade 1/2 diarrhea higher in the TYKERB + trastuzumab arm (53 percent vs. 41 percent; p=0.03). Two patients in the combination arm and one patient in the TYKERB monotherapy arm experienced symptomatic decreases in left ventricle ejection fracture (LVEF); one patient in the TYKERB + trastuzumab arm died due to a pulmonary thromboembolism with progressive malignant pleural effusions; two patients with LVEF decrease later recovered. Isolated cases of asymptomatic transient decreases in LVEF were noted in both treatment arms (1).

Additional Breast Cancer Data for Investigational Uses of TYKERB to be Presented at ASCO

GSK Oncology will also be presenting for the first time results of two studies evaluating TYKERB in combination with other targeted therapies, including TYKERB + pazopanib, GSK's investigational, oral, multikinase angiogenesis inhibitor, and TYKERB + bevacizumab. Final results from a trial evaluating TYKERB monotherapy in inflammatory breast cancer (IBC) will also be presented on-site. For more information on date and time of presentation, visit http://www.asco.org.

"The breadth of data to be presented at ASCO this year is truly remarkable and signifies the commitment of GSK Oncology to being at the forefront of cancer research," said Paolo Paoletti, M.D., Senior Vice President o
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... , SAN DIEGO, Nov. 19 Accumetrics, ... method for measuring platelet reactivity, announces that its market-leading ... in the POPular study, which was presented during a ... Association,s annual Scientific Sessions. The VerifyNow P2Y12 Test is ...
... 19 Perrigo Company (Nasdaq: PRGO ; TASE) today ... present at the Sidoti Emerging Growth Conference on Friday, November ... in New York City. , Perrigo Company is ... OTC and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) ...
Cached Medicine Technology:VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests 2
(Date:7/12/2014)... HealthDay Reporter SATURDAY, July 12, 2014 (HealthDay ... technique used to grind up uterine growths and remove them ... to other parts of a woman,s body, U.S. health advisers ... Drug Administration also said that women who do undergo the ... written consent stating that they understand the potential risks, the ...
(Date:7/12/2014)... 2014 Demand Response Management Systems is ... in reducing the imbalance between energy supply and demand. ... been rolled out (due to increasing pressure on the ... helps in controlling residential appliances and thermostats for load ... North American region, and with government mandates and benefits ...
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
(Date:7/12/2014)... (HealthDay News) -- Burn injuries increase in the summer as ... burn experts. Among those most vulnerable to these seasonal fire ... and often get burned by putting their hands on the ... the burn unit at Loyola University Medical Center in Maywood, ... adage of ,When you play with fire, you get burned, ...
(Date:7/12/2014)... 12, 2014 “After my mom’s stroke, she loss ... stroke and loss the use of his left side. Eating became ... way to help people like them enjoy eating again,” said an ... for the PATRICIA CAROL HALL PLATE (P C H PLATE). , ... more ergonomic way to eat for individuals who suffer from stroke, ...
Breaking Medicine News(10 mins):Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2
... for Radiation Oncology (ASTRO) applauds President Obama,s selection of ... the Centers for Medicare and Medicaid Services. ASTRO looks ... and Congress to implement critical healthcare reforms for patients ... providers to improve the quality of care patients receive. ...
... a key type of immune cell are higher in head and ... or HPV, according to researchers at the University of Michigan Comprehensive ... which tumors are most likely to respond to chemotherapy and radiation ... "In the past, we would give toxic chemotherapy to a ...
... ... account of his interest and research on improving ones state of life. This book helps ... as it strives to touch all walks of life. , ... Washington, D.C. (Vocus) April 26, 2010 -- Thomas Finn ...
... three of their cytoskeletonsactin, microtubules, and intermediate filamentsto metastasize, according ... Journal of Cell Biology ( www.jcb.org ). ... it can force through the basement membrane, which cordons off ... with enzymes that build up within extensions called invadopodia. How ...
... Victims of domestic violence endure significantly higher health costs ... a new study finds. Abuse victims had health care ... the first two years after the abuse ended and about ... continue to experience physical and emotional consequences even years after ...
... side effects, including reduced strength after shots, study finds ... which smoothes facial wrinkles through injections of the drug ... elbow," a new study finds. , But the researchers ... a potentially nettlesome side effect, according to the report ...
Cached Medicine News:Health News:Immune cells predict success of head and neck cancer treatment, U-M study finds 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2Health News:Domestic violence victims have higher health costs for years after abuse ends 2Health News:Domestic violence victims have higher health costs for years after abuse ends 3Health News:Botox Injections May Relieve Tennis Elbow Pain 2
... new and improved OrthoWedge® Healing Shoe offers ... on the forefoot while allowing patients to ... designed shorter wedge, an even larger portion ... ulcerations under the metatarsal heads and toes ...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
... The Epi-K is a fully automated ... surgeons to,perform a new refractive procedure ... to,mechanically cleave the epithelium from the,Bowmans ... laser ablation.,Epi-Lasik preserves the structural integrity,of ...
Medicine Products: